Company Analysis
Sign in

Parabilis Medicines, Inc. (PBLS)

Nasdaq: PBLS · Pharmaceutical Preparations · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.8
◀ Past 6.0● Present 6.5▶ Future 5.0
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Parabilis Medicines, Inc.’s names, not what it holds today.

Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 1 in 2023
Applications published
10
since 2001, to Dec 31, 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
FOG PHARMACEUTICALS, INC. a former name
named as the applicant on its applications, in US
0 granted
9 published
FOG PHARMACEUTICALS, INC. a former name
US, as the owner printed on each patent
2 granted
1 published
Parabilis Medicines, Inc. its own name
US, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 26, 202512,398,178Collections of peptides, peptide agents, and methods of use thereofBiotechnologyParabilis Medicines, Inc.
Dec 5, 202311,834,482Agents modulating beta-catenin functions and methods thereofBiotechnologyFOG PHARMACEUTICALS, INC.
Dec 14, 202111,198,713Agents modulating beta-catenin functions and methods thereofBiotechnologyFOG PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 28, 20242024/0391956STAPLED PEPTIDES AND METHODS THEREOFBiotechnologyFOG PHARMACEUTICALS, INC.
Nov 14, 20242024/0376151STAPLED PEPTIDES AND METHODS THEREOFAnalysis of biological materialsFOG PHARMACEUTICALS, INC.
Oct 31, 20242024/0360179STAPLED PEPTIDES AND METHODS THEREOFBiotechnologyFOG PHARMACEUTICALS, INC.
Apr 11, 20242024/0116985STAPLED PEPTIDES AND METHODS THEREOFPharmaceuticalsFOG PHARMACEUTICALS, INC.
Nov 9, 20232023/0357320HELICAL STAPLED PEPTIDES AND USES THEREOFBiotechnologyFOG PHARMACEUTICALS, INC.
Aug 31, 20232023/0271917AMINO ACIDSOrganic fine chemistryFOG PHARMACEUTICALS, INC.
Feb 16, 20232023/0046728TECHNOLOGIES USEFUL FOR ASSESSING PERMEABILITYBiotechnologyFOG PHARMACEUTICALS, INC.
Jul 7, 20222022/0213154AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOFBiotechnologyFOG PHARMACEUTICALS, INC. · patent 11,834,482 granted from it
Jun 17, 20212021/0179665COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOFBiotechnologyFOG PHARMACEUTICALS, INC. · patent 12,398,178 granted from it
Aug 6, 20202020/0247858AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOFBiotechnologyFOG PHARMACEUTICALS, INC. · patent 11,198,713 granted from it
What it applied for, 2024 to 2025: Biotechnology 2 · Pharmaceuticals 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PBLS · research, not advice